Novovax Covid jab tested in Blackpool reveals trial results of 89% efficacy
A Covid vaccine tested in Blackpool has an overall efficacy of 89.3 per cent, including against the now-predominant UK variant, results from its phase three trial in the UK showed.
Novovax said its life-saving cocktail is the “first vaccine to demonstrate not only high clinical efficacy against Covid-19 but also significant clinical efficacy against both the rapidly emerging UK and South Africa variants”.
Boss Stanley C. Erck added: “[The vaccine] has the potential to play an important role in solving this global public health crisis.”
The UK trial enrolled more than 15,000 people between 18-84, with 27 per cent over 65.
Efficacy was calculated to be 95.6 per cent against the original coronavirus strain and 85.6 per cent against the UK variant.
Clive Dix, chairman of the UK Vaccine Taskforce, said: “This is an incredible achievement that will ensure we can protect individuals in the UK and the rest of the world from this virus.”
Dr Rebecca Clark, who led trial efforts on the Fylde coast and enrolled the first UK participant at her GP practice in Layton, said she was “so proud”.
She tweeted: “Dedicated, transparent, and a great, great vaccine.”
The first person in the world to participate in the Novavax vaccine trial was Karen Eaves, a 49-year-old teacher from Bispham.
Last month, Karen shared her experience with the Gazette. You can read her story here.
Paul Worsley, a 46-year-old dad from Anchorsholme, was also one of the first volunteers to take part in the Novovax trials at Blackpool Vic.
You can read Paul's story here.
Thanks for reading. If you value what we do and are able to support us, a digital subscription is just £1 for your first month. Try us today by clicking here